TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Bridge to Treatment: The Therapeutic Workplace and Methadone Treatment

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Individuals were eligible if they were:~* at least 18 years old,~* reported injection drug use in the past 30 days,~* met the Diagnostic and Statistical Manual (DSM)-IV criteria for opioid dependence,~* reported using heroin at least 21 out of the past 30 days,~* provided an opiate-positive urine sample,~* showed visible signs of injection drug use (i.e., track marks),~* reported not receiving substance abuse treatment in the past 30 days,~* lived in Baltimore,~* and were unemployed.~Participants were excluded if they~* had current severe psychiatric disorders or chronic medical conditions that would interfere with their ability to participate in the workplace,~* reported current suicidal or homicidal ideation,~* had physical limitations that would prevent them from using a keyboard,~* had medical insurance coverage (as this would disqualify them from receiving interim methadone treatment),~* were pregnant or breastfeeding,~* or were currently considered a prisoner.~Eligible participants were invited to participate in a 4-week induction. Participants who attended the workplace for at least five minutes on two out of five workdays in the last week of induction were randomly assigned to one of three conditions and were invited to attend the workplace for an additional 26 weeks

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Usual Care Control (Type: NO_INTERVENTION): Participants in this group were offered employment in the Therapeutic Workplace without urinalysis testing or the methadone treatment requirement. They were offered the methadone treatment but were not required to join in order to gain access to the workplace.
- Methadone Contingency Group (Type: EXPERIMENTAL): Participants in this group were allowed to work and earn wages as long as they enrolled in the methadone treatment and continued to take does of methadone consistently (employment-based reinforcement).
- Methadone & Abstinence Contingency (Type: EXPERIMENTAL): Participants in this group were able to access work if they enrolled in the methadone treatment and consistently took their medication, but they also received a decrease in base pay if they test positive for opiates or cocaine on the drug screens (employment-based reinforcement).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Orlistat for the Treatment of Type I Hyperlipoproteinemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Type I hyperlipoproteinemia~2. Fasting serum triglyceride levels of greater than 1000 mg/dL~3. Age \> 8 years~Exclusion Criteria:~1. Secondary hypertriglyceridemias due to diabetes, renal disease, hypothyroidism, alcoholism and drug therapy such as estrogens and estrogen analogues, steroids, HIVprotease inhibitors, retinoic acid derivatives and interferons~2. Pregnant or lactating women~3. Significant liver disease (elevated transaminases \> 2 times upper limit of normal) Alcohol abuse (\> 7 drinks or 84 g per week for women and \> 14 drinks or 168 g per week for men)~4. Severe anemia (hematocrit \< 24%)~5. Drug use (cocaine, marijuana, LSD, etc.)~6. Major surgery in the past three months~7. Congestive heart failure~8. Serum creatinine greater than 2.5 mg/dL~9. Cancer within the past five years~10. Gastrointestinal surgery in the past~11. Current therapy with anti-coagulants, digoxin, and anti-arrhythmics~12. Current therapy with cyclosporine~13. Chronic malabsorption syndromes~14. Cholestasis~15. Acute illnesses such as acute pancreatitis in the last 8 weeks

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Orlistat (Type: EXPERIMENTAL): 120 mg of Orlistat will be given 3 times to patients weighing greater than 50 kg and patients weighing less than 40 kg will be given 60 mg of Orlistat 3 times a day for 3 months.
- Off drug (Type: NO_INTERVENTION): Standard therapy will be given for three months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel Group Trial to Investigate the Efficacy and Safety of SPM 927 (200mg/Day and 400mg/Day) as Adjunctive Therapy in Subjects With Partial Seizures With or Without Secondary Generalization

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* partial seizures with or without secondary generalization~Exclusion Criteria:~* subjects received SPM 927 in a previous trial

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial To Evaluate The Efficacy of Magnetic Resonant Therapy in Autism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Primary diagnosis of Autism Spectrum Disorder by Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) rendered by the examination and sufficient Childhood Autism Rating Scale 2nd Edition (CARS-2) score to qualify as autism.~* CARS-2 score between 36 and 47 inclusively~* Age between 4 and 12 years (at day of informed consent)~* Child must suffer disrupted sleep patterns defined as a minimum of 3 nights per week of delayed onset of sleep or night-time awakenings. If these are medicated with mild sedatives or melatonin and corrected, the requirement for medication or melatonin will qualify as evidence of a sleep disorder.~Exclusion Criteria:~* Diagnosis of Asperger's Disorder, Pervasive Developmental Disorder Not Otherwise specified~* History of clinically significant traumatic brain injury~* Any condition associated with increased intracranial pressure~* Cerebral Aneurysm~* Down's Syndrome or other chromosomal abnormality~* EEG abnormalities that indicate seizure risk~* Intracranial implant~* Unstable medical condition not otherwise specified~* Clinically significant organic disease unrelated to autism

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Magnetic Resonance Therapy (MRT)-Active (Type: EXPERIMENTAL): Magnetic Field, modulated as per EEG analysis, is active for 6 seconds every minute for 30 minutes per day, 5 days per week x 5 weeks.
- Magnetic Resonance Therapy (MRT)-Sham (Type: SHAM_COMPARATOR): Magnetic field is not active, but a sham coil is used, for 6 seconds every minute for 30 minutes per day, 5 days per week x 5 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Of The Effects Of OC000459 In Subjects Known To Suffer From Grass Pollen Induced Allergic Rhinitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males aged 18 to 50 years with a history of symptoms of grass pollen related allergic rhinitis within the previous two years.~* Subjects must be free from significant cardiac, pulmonary, gastrointestinal, hepatic, renal, haematological, neurological and psychiatric disease as determined by history, physical examination and screening investigations.~* FEV1 within normal limits (≥90% of predicted).~* Atopy defined by a positive cutaneous response to mixed grass pollen within the last 12 months or at screening.~* Asymptomatic at screening~* Non smokers for at least the past 12 months~Exclusion Criteria:~* Medical conditions likely to affect the outcome of the study.~* Nasal conditions likely to affect the outcome of the study, i.e. nasal septal perforations, nasal polyps, sinus disease, chronic nasal obstruction, or other nasal diseases.~* Presence of any respiratory disease other than a history of mild stable asthma not requiring treatment and associated with normal lung function~* Immunotherapy treatment course including inhaled or local corticosteroids in the past 28 days.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- OC000459 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Functional Effects of Botox on the Brain Using MRS and fMRI

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Females~* Ages 30-40 years of age~* Right-handed~* Normal or corrected-to-normal vision~* No history of psychiatric, neurological, or medical co-morbidities that might interfere with normal brain functioning~* Fluent in English~* Moderate to severe glabellar lines~Exclusion Criteria:~* Pregnancy~* Ferrous metal, a pacemaker, or other battery-operated device implanted in the body~* Claustrophobia~* Known hypersensitivity to Botulinum Toxin~* Infection on the forehead or between the eyes~* Urinary tract infection

- Gender: FEMALE
- Minimum Age: 30 Years
- Maximum Age: 40 Years
- Healthy Volunteers: t

Study Arms:
- MRI Scans Pre and Post-Botox Injection (Type: EXPERIMENTAL): Participants will receive MRI scans pre and post-Botox injection, including magnetic resonance spectroscopy, structural, and functional MRI.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: To Assess the Efficacy of Esomeprazole 40 mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged 20 years or more~* Documented history of reflux esophagitis verified by endoscopy in the past, including the grade of Los Angeles (LA) classification (Lundell LR et al 1999) before treatment~* Ongoing (until date of Visit 1) treatment with rabeprazole 20 mg, given once daily, for a period of 4 to 8 weeks. The subject must take Rabeprazole at least 4 days a week in the past 7 days prior to Visit 1.~* Persisting symptoms of heartburn during the past 7 days prior to Visit 1, judged by the investigator(s) as follows: At least 2 days with moderate (i.e. discomfort sufficient to cause interference with normal activities) to severe symptoms (i.e. incapacitating, with inability to perform normal activities) OR At least 4 days with symptoms including mild ones (i.e. awareness of sign or symptom, but easily tolerated).~* The subject needs to be able to understand and read the official languages of the country.~Exclusion Criteria:~* Use of other PPIs and/or H2RA during rabeprazole treatment~* Previous use of esomeprazole 40 mg during the 12 weeks before enrolment~* Current or historical evidence of gastrointestinal pathology~* History, signs or symptoms of clinically significant or uncontrolled cardiovascular, pulmonary, renal, endocrine, hematologic, neurologic, psychiatric pancreatic or hepatic disease as judged by the investigator to interfere with the conduct of the study, the interpretation of study results, subject compliance, or the health of the subject during the study.~* Documented upper gastrointestinal surgery such as gastric resection, vagotomy and/or pyloroplasty, hiatus hernia surgery or fundoplication. Note: endoscopic polypectomy, endoscopic mucosal resection, endoscopic submucosal dissection or simple suturing of an ulcer are not exclusion criteria.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): One arm: esomeprazole 40 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Heme Iron Polypeptide for Iron Deficiency Anemia in Chronic Renal Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* eGFR \&lt; 30 mL/min~* Hb 90-110 g/L~* Age \&gt; 18~* Not on renal replacement therapy~* Transferrin saturation \&lt; 20% OR Ferritin \&lt;100 mcg/L~* B12 \& folate within reference range~Exclusion Criteria:~1. Iron overload (Tsat \> 50% or ferritin \> 800 μg/L);~2. malignancy; recurrent gastro-intestinal bleeding, major surgery or infection within the last 3 months;~3. parenteral iron therapy, blood transfusion within the last 3 months;~4. pregnancy;~5. contraindication to any study medication and;~6. inability or refusal to give consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Heme Iron (Type: EXPERIMENTAL): Heme Iron Polypeptide 11mg PO tid for 6 months
- Venofer (Type: ACTIVE_COMPARATOR): Venofer q month IV x 6 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Budesonide / Formoterol in Treatment of Exacerbations of COPD

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* smoking-induced COPD according to ATS criteria~* FEV1 \<85% of predicted at enrolment and \<70% of predicted but \> 0.7 Liter at Exacerbation~* FEV1/IVC ratio \<88% of predicted for men and \<89% for women~Exclusion Criteria:~* history of asthma~* known hypersensitivity to the study drugs~* serious concomitant diseases~* pregnancy or lactating~* abnormal Chest X-ray or blood gasses

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tirofiban in Stenting for Long Coronary Lesion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age between 18y\~80y, with symptomatic coronary disease~* At least one lesion length more than 40mm to be treated by overlapping drug-eluting stents in major epicardial coronary vessel~Exclusion Criteria:~* Aspirin or clopidogrel intolerance~* Lesions length less than 40mm, or overlapping stent length less than 40mm~* Bifurcation lesions need to be treated by two stents~* Patients with acute coronary syndrome and elevated baseline cardiac enzyme (CK-MB)~* Left ventricular ejection fraction less than 0.35~* Baseline estimated GFR less than 30~* Estimated life time less than one year~* Refuse to sign the informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Control group (Type: PLACEBO_COMPARATOR): normal saline was applied to those randomized to control group, with same use as tirofiban
- Tirofiban group (Type: EXPERIMENTAL): after angioram, and before guiding catheter engagement: 10μg/kg bolus followed by 0.15μg/kg/min maintenance infusion

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Improving Safety of Antivenom in People Bitten by Snakes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Above 12 years of age~* Patients admitted to hospital after snake bite in whom antivenom is indicated~* Patients who give informed consent~Exclusion Criteria:~* Patients who are pregnant or nursing~* Patients who are currently taking beta- or alpha-adrenoceptor antagonists, or tricyclic antidepressants~* Patients in whom adrenaline may be contraindicated (this may include patients with the following: history of ischaemic heart disease, stroke, uncontrolled hypertension, and tachyarrhythmias)

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects of Minocycline on Cytokine Levels in Severe Meibomian Gland Dysfunction

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* patients with stage 3 or 4 meibomian gland dysfunction~* moderate or marked symptoms of ocular discomfort, itching, or photophobia with limitations of activities~* moderate or severe meibomian gland dysfunction clinical signs~* mild to moderate conjunctival and peripheral corneal staining or increased conjunctival and corneal staining, including central staining~* increased signs of inflammation : moderate or severe conjunctival hyperemia, phlyctenulae~Exclusion Criteria:~* history of previous ocular or intraocular surgery~* evidence of acute or chronic infections or inflammation of the cornea and conjunctiva~* ocular allergy~* autoimmune disease~* history of intolerance or hypersensitivity to any component of the study medications~* use of topical ocular medications~* wearing contact lenses during the study period~* presence of current punctal occlusion~* pregnancy~* lactating women~* children

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Minocycline treatment group (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dexmedetomidine Facilitate Analgesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: HEALTH_SERVICES_RESEARCH
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* aged from 18 to 80 years old~* American Association of anesthesiologists (ASA) grade Ⅱ \~ IV~* body mass index (BMI) 18.5-40~* planning undergoing peripheral nerve block~Exclusion Criteria:~* incomplete effect of nerve block~* Alzheimer's disease~* implanted cardiac pacemakers~* mental illness~* epilepsy~* autonomic nervous system diseases~* projected the duration of the operation was more than 3 hours

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Group 1 (Type: EXPERIMENTAL): Dexmedetomidine group (Group DEX) was given 1.5ug/kg/h Dexmedetomidine continuous infusion Dexmedetomidine group (Group DEX)
- Group 2 (Type: ACTIVE_COMPARATOR): Midazolam group (Group MID) was continuously pumped with 0.05mg/kg/h midazolam

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
* Histologically or cytologically confirmed adenocarcinoma of the breast~* Subjects with early stage disease who are estrogen receptor positive and who have completed their treatment pathway (surgery, chemo-therapy, radiation, and/or hormone therapy) and are currently on or will initiate aromatase inhibitor therapy, and are expected to stay on aromatase inhibitor therapy for the duration of the 24-month study~* All treatment pathway must be completed ≥ 4 weeks prior to study entry, and all acute toxic effect of any above therapy must be resolved to ≤ Grade 1 by National Cancer Institution (NCI) Common Terminology Criteria for Adverse Events (CTCAE)~* Female \> 18 years of age~* ECOG Performance status 0 and 1~* Lumbar spine, total hip or femoral neck BMD equivalent to a t-score classification of -1.0 to -2.5~* Subject is willing and able to provide signed consent before any study-specific procedure~Other criteria also apply.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- AMG 162 / Denosumab (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete